TABLE 1.
Clinical characteristics of the patients with HCC
| Characteristic | Low expression of VEGFA | High expression of VEGFA | p |
|---|---|---|---|
| n | 187 | 187 | |
| Gender, n (%) | |||
| Female | 43 (11.5%) | 78 (20.9%) | <0.001 |
| Male | 144 (38.5%) | 109 (29.1%) | |
| Age (years), n (%) | |||
| <=60 | 96 (25.7%) | 81 (21.7%) | 0.133 |
| >60 | 90 (24.1%) | 106 (28.4%) | |
| Height (cm), n (%) | |||
| <170 | 91 (26.7%) | 110 (32.3%) | 0.010 |
| > = 170 | 84 (24.6%) | 56 (16.4%) | |
| Weight (kg), n (%) | |||
| <=70 | 84 (24.3%) | 100 (28.9%) | 0.050 |
| >70 | 92 (26.6%) | 70 (20.2%) | |
| BMI (kg/cm2), n (%) | |||
| <=25 | 92 (27.3%) | 85 (25.2%) | 0.981 |
| >25 | 82 (24.3%) | 78 (23.1%) | |
| AFP (ng/ml), n (%) | |||
| <=400 | 114 (40.7%) | 101 (36.1%) | 0.139 |
| >400 | 27 (9.6%) | 38 (13.6%) | |
| Child‐Pugh grade, n (%) | |||
| A | 118 (49%) | 101 (41.9%) | 0.647 |
| B | 12 (5%) | 9 (3.7%) | |
| C | 0 (0%) | 1 (0.4%) | |
| T stage, n (%) | |||
| T1 | 103 (27.8%) | 80 (21.6%) | 0.035 |
| T2 | 47 (12.7%) | 48 (12.9%) | |
| T3 | 30 (8.1%) | 50 (13.5%) | |
| T4 | 5 (1.3%) | 8 (2.2%) | |
| N stage, n (%) | |||
| N0 | 124 (48.1%) | 130 (50.4%) | 0.623 |
| N1 | 1 (0.4%) | 3 (1.2%) | |
| M stage, n (%) | |||
| M0 | 134 (49.3%) | 134 (49.3%) | 1.000 |
| M1 | 2 (0.7%) | 2 (0.7%) | |
| Pathologic stage, n (%) | |||
| Stage I | 96 (27.4%) | 77 (22%) | 0.048 |
| Stage II | 45 (12.9%) | 42 (12%) | |
| Stage III | 32 (9.1%) | 53 (15.1%) | |
| Stage IV | 3 (0.9%) | 2 (0.6%) | |
| Histologic grade, n (%) | |||
| G1 | 33 (8.9%) | 22 (6%) | 0.115 |
| G2 | 95 (25.7%) | 83 (22.5%) | |
| G3 | 53 (14.4%) | 71 (19.2%) | |
| G4 | 5 (1.4%) | 7 (1.9%) | |
| Residual tumour, n (%) | |||
| R0 | 166 (48.1%) | 161 (46.7%) | 0.044 |
| R1 | 4 (1.2%) | 13 (3.8%) | |
| R2 | 1 (0.3%) | 0 (0%) | |
| Vascular invasion, n (%) | |||
| No | 106 (33.3%) | 102 (32.1%) | 1.000 |
| Yes | 56 (17.6%) | 54 (17%) | |